Literature DB >> 27287520

Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery.

Diane V Doughty1, Corbin Z Clawson2, William Lambert2, J Anand Subramony2.   

Abstract

Subcutaneous injection allows for self-administration of monoclonal antibodies using prefilled syringes, autoinjectors, and on-body injector devices. However, subcutaneous injections are typically limited to 1 mL due to concerns of injection pain from volume, viscosity, and formulation characteristics. Back pressure can serve as an indicator for changes in subcutaneous mechanical properties leading to pain during injection. The purpose of this study was to investigate subcutaneous pressures and injection site reactions as a function of injection volume and flow rate. A pressure sensor in the fluid path recorded subcutaneous pressures in the abdomen of Yorkshire swine. The subcutaneous tissue accommodates large-volume injections and with little back pressure as long as low flow rates are used. A 1 mL injection in 10 seconds (360 mL/h flow rate) generated a pressure of 24.0 ± 3.4 kPa, whereas 10 mL delivered in 10 minutes (60 mL/h flow rate) generated a pressure of 7.4 ± 7.8 kPa. After the injection, the pressure decays to 0 over several seconds. The subcutaneous pressures and mechanical strain increased with increasing flow rate but not increasing dose volume. These data are useful for the design of injection devices to mitigate back pressure and pain during subcutaneous large-volume injection.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biocompatibility; device; injectables; injectors; monoclonal antibody; pain; parenteral; physiological model; skin; subcutaneous

Mesh:

Substances:

Year:  2016        PMID: 27287520     DOI: 10.1016/j.xphs.2016.04.009

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Sensitivity Analysis.

Authors:  Peng Hou; Fudan Zheng; Clairissa D Corpstein; Lei Xing; Tonglei Li
Journal:  Pharm Res       Date:  2021-06-02       Impact factor: 4.200

2.  Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
.

Authors:  Meena Jain; Diane Doughty; Corbin Clawson; Xiaobai Li; Nicholas White; Balaji Agoram; René van der Merwe
Journal:  Int J Clin Pharmacol Ther       Date:  2017-07       Impact factor: 1.366

3.  Novel cannula design improves large volume auto-injection rates for high viscosity solutions.

Authors:  Bruce C Roberts; Christopher Rini; Rick Klug; Douglas B Sherman; Didier Morel; Ronald J Pettis
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

Review 4.  Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.

Authors:  Carlos Bendicho-Lavilla; Iria Seoane-Viaño; Francisco J Otero-Espinar; Asteria Luzardo-Álvarez
Journal:  Acta Pharm Sin B       Date:  2021-08-10       Impact factor: 11.413

5.  Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects.

Authors:  Wendy D Woodley; Wen Yue; Didier R Morel; Audrey Lainesse; Ronald J Pettis; Natasha G Bolick
Journal:  Clin Transl Sci       Date:  2021-03-25       Impact factor: 4.689

Review 6.  Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.

Authors:  Beate Bittner; Wolfgang Richter; Johannes Schmidt
Journal:  BioDrugs       Date:  2018-10       Impact factor: 5.807

7.  Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults.

Authors:  Wendy D Woodley; Didier R Morel; Diane E Sutter; Ronald J Pettis; Natasha G Bolick
Journal:  Clin Transl Sci       Date:  2021-11-10       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.